Short Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Grows By 53.3%

Repare Therapeutics Inc. (NASDAQ:RPTX) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,300,000 shares, an increase of 53.3% from the December 15th total of 847,800 shares. Approximately 4.3% of the shares of the stock are short sold. Based on an average daily volume of 380,100 shares, the days-to-cover ratio is presently 3.4 days.

Analyst Ratings Changes

A number of research analysts recently weighed in on RPTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a research note on Friday, November 8th. Bloom Burton lowered Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 10th. Lifesci Capital reissued a “market perform” rating on shares of Repare Therapeutics in a research note on Friday, December 13th. Finally, Stifel Nicolaus lowered their price target on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, December 13th.

Repare Therapeutics Stock Performance

Shares of RPTX remained flat at $1.28 during midday trading on Friday. The company’s stock had a trading volume of 189,272 shares, compared to its average volume of 500,187. Repare Therapeutics has a twelve month low of $1.20 and a twelve month high of $8.49. The business has a fifty day simple moving average of $2.28 and a 200 day simple moving average of $2.97. The company has a market capitalization of $54.41 million, a PE ratio of -0.64 and a beta of 0.88.

Institutional Investors Weigh In On Repare Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC grew its stake in shares of Repare Therapeutics by 1,471.7% in the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock valued at $29,000 after buying an additional 7,800 shares during the period. Stifel Financial Corp lifted its holdings in Repare Therapeutics by 36.4% in the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after acquiring an additional 13,800 shares during the last quarter. Vontobel Holding Ltd. grew its position in Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after acquiring an additional 4,000 shares during the period. Exchange Traded Concepts LLC grew its position in Repare Therapeutics by 21.2% in the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after acquiring an additional 8,809 shares during the period. Finally, Blue Owl Capital Holdings LP increased its stake in Repare Therapeutics by 8.0% during the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock worth $11,129,000 after acquiring an additional 250,000 shares during the last quarter. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.